Tofacitinib Reduces KL-6 Levels in Patients With Rheumatoid Arthritis-Associated Interstitial Lung Disease. Results Of A Phase II Investigator-Initiated Study.

Study limitation reported by the research below: “No control/placebo arm was included; efficacy conclusions (FVC decline, KL-6 reduction) are descriptive only and cannot establish causation.”